Related Experiment Videos

Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers

P Osin, T Crook, T Powles

Lancet (London, England)

|May 30, 1998

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.

ESMO open·2026

HER1-HER4 expression and co-expression in advanced urothelial carcinoma.

ESMO open·2026

Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis.

ESMO open·2026

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026

Higher rates of immune-related adverse events in circulating tumor DNA (ctDNA)-negative patients following adjuvant checkpoint inhibitor therapy.

ESMO open·2026

See all related articles